These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 39301549)

  • 21. Clinical feasibility study of early 30-minute dynamic FDG-PET scanning protocol for patients with lung lesions.
    Du F; Wumener X; Zhang Y; Zhang M; Zhao J; Zhou J; Li Y; Huang B; Wu R; Xia Z; Yao Z; Sun T; Liang Y
    EJNMMI Phys; 2024 Mar; 11(1):23. PubMed ID: 38441830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The correlation between PD-L1 expression and metabolic parameters of
    Xu X; Li J; Yang Y; Sang S; Deng S
    Clin Imaging; 2022 Sep; 89():120-127. PubMed ID: 35797878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1 in Lung Adenocarcinoma: Insights into the Role of
    Cui Y; Li X; Du B; Diao Y; Li Y
    Cancer Manag Res; 2020; 12():6385-6395. PubMed ID: 32801879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of PD-L1 Expression in Non-Small Cell Lung Cancers Using [
    Wu Y; Xu D; Gu Y; Li G; Wang H; Cao M; Wei W; Wan P; Guan Y; Chen X; Xie F
    Small Methods; 2024 Jun; ():e2400358. PubMed ID: 38880776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on
    Takada K; Toyokawa G; Okamoto T; Baba S; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Honda H; Oda Y; Maehara Y
    Cancer Med; 2017 Nov; 6(11):2552-2561. PubMed ID: 28980429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result.
    Jiang M; Sun D; Guo Y; Guo Y; Xiao J; Wang L; Yao X
    Acad Radiol; 2020 Feb; 27(2):171-179. PubMed ID: 31147234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between
    Zhao L; Liu J; Wang H; Shi J
    Br J Radiol; 2021 Mar; 94(1119):20200397. PubMed ID: 33492995
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Wu X; Huang Y; Li Y; Wang Q; Wang H; Jiang L
    Ann Nucl Med; 2019 Sep; 33(9):647-656. PubMed ID: 31165974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The value on SUV-derived parameters assessed on
    Liao X; Liu M; Li S; Huang W; Guo C; Liu J; Xiong Y; Zhang J; Fan Y; Wang R
    BMC Med Imaging; 2023 Apr; 23(1):49. PubMed ID: 37020286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Novel Approach Using FDG-PET/CT-Based Radiomics to Assess Tumor Immune Phenotypes in Patients With Non-Small Cell Lung Cancer.
    Zhou J; Zou S; Kuang D; Yan J; Zhao J; Zhu X
    Front Oncol; 2021; 11():769272. PubMed ID: 34868999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images.
    Mu W; Jiang L; Shi Y; Tunali I; Gray JE; Katsoulakis E; Tian J; Gillies RJ; Schabath MB
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34135101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
    Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
    J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Polverari G; Ceci F; Bertaglia V; Reale ML; Rampado O; Gallio E; Passera R; Liberini V; Scapoli P; Arena V; Racca M; Veltri A; Novello S; Deandreis D
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32380754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A CT-derived deep neural network predicts for programmed death ligand-1 expression status in advanced lung adenocarcinomas.
    Zhu Y; Liu YL; Feng Y; Yang XY; Zhang J; Chang DD; Wu X; Tian X; Tang KJ; Xie CM; Guo YB; Feng ST; Ke ZF
    Ann Transl Med; 2020 Aug; 8(15):930. PubMed ID: 32953730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Noninvasive evaluation of tumor immune microenvironment in patients with clear cell renal cell carcinoma using metabolic parameter from preoperative 2-[
    Wu C; Cui Y; Liu J; Ma L; Xiong Y; Gong Y; Zhao Y; Zhang X; Chen S; He Q; Zhang J; Liu M; Fan Y
    Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):4054-4066. PubMed ID: 33978830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Negative Correlation Between
    Wu L; Liu J; Wang S; Bai M; Wu M; Gao Z; Li J; Yu J; Liu J; Meng X
    Front Endocrinol (Lausanne); 2022; 13():913631. PubMed ID: 35846323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
    Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combining PD-L1 Expression and Standardized Uptake Values in FDG-PET/CT Can Predict Prognosis in Patients With Resectable Non-Small-Cell Lung Cancer.
    Miyazawa T; Otsubo K; Sakai H; Kimura H; Chosokabe M; Morikawa K; Furuya N; Marushima H; Kojima K; Mineshita M; Koike J; Saji H
    Cancer Control; 2021; 28():10732748211038314. PubMed ID: 34384268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Graph Neural Network Model for Prediction of Non-Small Cell Lung Cancer Lymph Node Metastasis Using Protein-Protein Interaction Network and
    Ju H; Kim K; Kim BI; Woo SK
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An [
    Meng N; Feng P; Yu X; Wu Y; Fu F; Li Z; Luo Y; Tan H; Yuan J; Yang Y; Wang Z; Wang M
    Eur Radiol; 2024 Jan; 34(1):318-329. PubMed ID: 37530809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.